- Trial phase
- Phase 1
- Time to market
- At least 5-7 years, assuming successful Phase 1, Phase 2, and Phase 3 trials. The drug is currently in Phase 1 dose-escalation with no efficacy data yet.
- Why 2/10
- No hard, dated binary catalyst is scheduled for IM-3050 in the next ~12 months. The drug is in Phase 1 dose-escalation (first patient dosed July 2026) with no announced timeline for data readout. Immunome's primary near-term catalyst is varegacestat's PDUFA date of April 28, 2027. IM-3050 is an early-stage pipeline asset that represents a small portion of the company's overall value.
IM-3050 is an early Phase 1 program with no near-term binary catalyst. The next meaningful update would likely be initial safety/dosing data from the ongoing Phase 1 trial, but no timeline for that readout has been announced. Immunome's stock is primarily driven by varegacestat (PDUFA April 28, 2027) and IM-1021 (ASH 2026 data), not IM-3050.
Price Chart
Executive Summary
IM-3050 is Immunome Inc.'s (Nasdaq: IMNM) lead radioligand therapy candidate, a fibroblast activation protein (FAP)-targeted treatment that delivers radioactive lutetium-177 to FAP-expressing advanced solid tumors. The drug entered Phase 1 clinical development in July 2026 with the first patient dosed in an open-label, multicenter dose-escalation and expansion study. Preclinical data were presented at AACR 2024. IM-3050 is an early-stage asset within Immunome's broader pipeline, which is currently dominated by varegacestat (PDUFA April 28, 2027 for desmoid tumors) and the IM-1021 ADC program. No near-term binary catalyst is scheduled for IM-3050 specifically, making it a minor driver of the stock's valuation at this stage.
How It Works
IM-3050 is a radioligand therapy, a type of targeted radiation treatment. It works by attaching a radioactive isotope (lutetium-177) to a molecule that seeks out and binds to fibroblast activation protein (FAP), a protein found on the surface of cells in many types of solid tumors. Once bound, the radiation delivers a localized dose to kill tumor cells while largely sparing healthy tissue. Think of it as a smart bomb that delivers radiation directly to cancer cells.
Trial Status
IM-3050 is in an open-label, multicenter Phase 1 dose-escalation and expansion trial for patients with FAP-expressing advanced solid tumors. The first patient was dosed on July 20, 2026. The trial is evaluating safety, tolerability, dosimetry, pharmacokinetics, and preliminary antitumor activity. No interim data have been reported as of November 2026.
The Two-Sided Case
Upcoming Catalysts
- Initial safety and dosing data from the Phase 1 trial (no date announced)
- Potential future expansion cohort data (no date announced)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Immunome Inc. 8-K IMNM ·Originating report